ICU Medical to Acquire Hospira’s Infusion Systems for $1 Billion
ICU Medical, Inc. and Pfizer, Inc. have entered into a definitive agreement under which ICU Medical will acquire Hospira Infusion Systems (Pfizer’s global infusion therapy business) for $1 billion. The infusion systems business includes IV pumps, solutions and devices. The union is expected to create a pure-play infusion therapy company, competitive in the U.S. and global market (with direct operations in more than 20 countries), with estimated pro forma combined revenues of about $1.45 billion. It will also “eliminate our single customer concentration issue,” according to Vivek Jain, CEO of ICU Medical.
“The combination of these two businesses is the natural evolution of a productive relationship that began more than 20 years ago when Hospira began integrating ICU Medical’s needlefree technology into their infusion offering globally,” said Jain in a press release.
Related Articles
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
On the journey to full-scale production for medical devices incorporating optics, a series of steps early in the process can make all the difference for successfully launching new products and introducing next-generation upgrades. This article discusses four considerations for a…
-
You’d think there’s not much to the concept of an alarm. A warning sounds in a room, or a red light flashes, and it has your attention. You know something must be wrong. But in a setting where a cacophony…
-
Baxter Hillrom is recalling its WatchCare Incontinence Management System (IMS) following reports that the radiofrequency emissions (RF) from WatchCare devices may interfere with other medical devices.
